News | September 02, 2021
Morpen Laboratories to transfer its medical devices business to a wholly owned subsidiary
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
Coordinated and collaborative efforts will strongly contribute to the achievement of shared goals faster: Mandaviya
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old
It is estimated that over 11,000 children across Europe, Middle East, and Africa are affected by achondroplasia and could be eligible for treatment with Voxzogo
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
The company has to approach the DCGI for approval to commence the trials
Subscribe To Our Newsletter & Stay Updated
